Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
The research, published in "Diabetes, Obesity, and Metabolism," illustrated that a variance in dosage or type of drug can impact results
The consensus analyst rating for Natco Pharma is 'Hold', with an average price target suggesting potential upside, indicating that while opportunities are significant, the path forward requires careful navigation of regulatory and legal challenges
Two separate measurements were performed on each sample, one that measured a pTau217-specific peptide and one for a t-Tau-specific peptide
Daeihamed M, Dadashzadeh S, Haeri A, Akhlaghi MF
Early access through telehealth and retail channels is encouraging, but investors need to see whether prescriptions can scale beyond early adopters and whether payer access improves meaningfully
US$ 20.86
US$ 27.58
US$ 21.61
US$ 22.06
